Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-1463
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease ; volume:129 ; number:7 ; day:3 ; month:5 ; year:2022 ; pages:889-894 ; date:7.2022
Journal of neural transmission ; 129, Heft 7 (3.5.2022), 889-894, 7.2022
- Creator
-
Lau, Yue Hui
Leta, Valentina
Rukavina, Katarina
Parry, Miriam
Ann Natividad, Jenny
Metta, Vinod
Chung-Faye, Guy
Chaudhuri, K. Ray
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00702-022-02506-4
- URN
-
urn:nbn:de:101:1-2022081422081171517843
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lau, Yue Hui
- Leta, Valentina
- Rukavina, Katarina
- Parry, Miriam
- Ann Natividad, Jenny
- Metta, Vinod
- Chung-Faye, Guy
- Chaudhuri, K. Ray
- SpringerLink (Online service)
Other Objects (12)
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Transdermal rotigotine for the perioperative management of Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Transdermal rotigotine for the perioperative management of Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Transdermal rotigotine for the perioperative management of Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
Helicobacter pylori infection and Parkinson’s Disease: etiology, pathogenesis and levodopa bioavailability
PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease